How Merck uses patents to help maintain Keytruda’s exorbitant price; International Consortium of Investigative Journalists, April 13, 2026

 Denise Ajiri and Antonio Cucho Gamboa, International Consortium of Investigative Journalists ; How Merck uses patents to help maintain Keytruda’s exorbitant price

"Merck’s original patents for Keytruda are set to expire in 2028. But Merck, using a strategy known as “evergreening,” has filed hundreds of additional patents that could protect Keytruda’s dominance well beyond that year.

ICIJ analyzed 180 U.S. patent applications related to Keytruda, provided by the Initiative for Medicines, Access & Knowledge (I-MAK), a nonprofit that examines inequities in the patent system. These were linked to 1,032 additional patent filings around the world tied to the drug. From this universe, ICIJ identified active U.S. patents that illustrate Merck’s strategy of maintaining market exclusivity.

Patents can have different status, including active, pending, abandoned, expired, or others. Explore Merck’s active U.S. Keytruda patents below."

Tariffs on Medicines From Europe Stand to Cost Drugmakers Billions; The New York Times, July 28, 2025

 Rebecca Robbins, The New York Times; Tariffs on Medicines From Europe Stand to Cost Drugmakers Billions

"The trade deal reached between the United States and the European Union on Sunday will impose a 15 percent tariff on imported medicines from Europe. Drugmakers manufacture some of their biggest and best-known blockbusters there, including Botox, the cancer medication Keytruda and popular weight-loss drugs like Ozempic...

Pharmaceutical products are Europe’s No. 1 export to the United States...

Europe manufactures the active ingredients for 43 percent of the brand-name drugs consumed in the United States, according to U.S. Pharmacopeia, a nonprofit that tracks the drug supply chain. No other region produces a greater share.

Europe also makes active ingredients for 18 percent of the generic drugs taken in the United States, which have lower prices and account for a vast majority of Americans’ prescriptions."